Showing 1851-1860 of 2652 results for "".
- Nidek Launches LPM Low Power Mode for YLC-500 Vixihttps://modernod.com/news/nidek-launches-lpm-low-power-mode-for-ylc-500-vixi/2476744/Nidek has announced the launch of LPM optional software, a low power mode for the YLC-500 Vixi laser photocoagulator. LPM delivers a therapeutic effect to the retina by decreasing the laser power during photocoagulati
- Pre-Pilot Clinical Trial from Ocutrx Vision Technologies Yields Exciting Results for Patients with AMDhttps://modernod.com/news/pre-patient-trial-from-ocutrx-vision-technologies-yields-exciting-results-for-patients-with-amd/2476659/Ocutrx Vision Technologies announced the results of the first pre-pilot clinical trial for the company’s Oculenz AR glasses. In the single arm crossover study of subjects with advanced macular degeneration, the Oculenz AR glasses significantly improved the ability of subjects to read small letter
- Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disordershttps://modernod.com/news/invitae-announces-id-your-ird-program-to-expand-access-to-genetic-testing-for-inherited-retinal-disorders/2476648/Invitae announced the launch of “ID YOUR IRD,” an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD). “Identifying the genetic cause of an inherit
- Three-Year Clinical Trial Results Support Iluvien Launch in Europe for Prevention of Relapse in Recurrent Noninfectious Uveitis Affecting the Posterior Segmenthttps://modernod.com/news/three-year-clinical-trial-results-support-iluvien-launch-in-europe-for-prevention-of-relapse-in-recurrent-noninfectious-uveitis-affecting-the-posterior-segment/2476635/Alimera Sciences announced 3-year followup data from the phase 3 clinical trial for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIPU). The data will support the company’s pla
- Ivantis Announces 3-Year Results from FDA Clinical Trial Demonstrating Long-Term Reduction of Severe Major Surgeries for Glaucoma Patientshttps://modernod.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/Ivantis, developer of the Hydrus Microstent, announced the 3-year results from the HORIZON pivotal study. The 2-year results, which were the foundation of FDA approval, were presented in November 2017, and were recently published in the journal Ophthalmology.
- EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-2019-arvo-annual-meeting/2476523/EyePoint Pharmaceuticals announced the presentation of 36-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18-mg micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The data
- Improved Premium IOLs Will Drive Growth in the Global IOL Market Over the Next 5 Yearshttps://modernod.com/news/improved-premium-iols-will-drive-growth-in-the-global-iol-market-over-the-next-5-years/2476449/Innovation in premium lens technology will fuel patient demand in the global IOL market over the next 5 years, according to a Market Scope report. The improved technology will provide better visu
- Survey: Physicians Generate an Average of $2.4 Million a Year Per Hospitalhttps://modernod.com/news/survey-physicians-generate-an-average-of-2-4-million-a-year-per-hospital/2479591/While physicians are key providers of medical care at the nation’s hospitals, a new survey confirms they also are major drivers of hospital revenue. According to the survey, physicians generate an average $2,378,727 per year in net revenue on behalf of their af
- Retreatment With A Single TearCare Treatment Continues To Provide Relief For Patients With Dry Eye Diseasehttps://modernod.com/news/retreatment-with-a-single-tearcare-treatment-continues-to-provide-relief-for-patients-with-dry-eye-disease/2476302/A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment for dry eye disease, according to a company news release. The
- One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy Presentedhttps://modernod.com/news/one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-angiogenesis-symposium/2476306/Regeneron Pharmaceuticals announced that positive detailed 1-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR)